Masthead
PeptideRank editorial bylines
PeptideRank publishes under 3 editorial bylines covering provider pricing, women's health and clinical evidence. These are publisher-owned coverage desks, not individual clinicians or independent medical reviewers. Their names describe subject areas, not staff headcount or qualifications. PeptideRank is responsible for the content. See our editorial policy for the research method and use the contact details below for corrections.
PeptideRank coverage of provider pricing, plan terms and pharmacy disclosures, with links to the provider reviews and comparisons published under this byline.
- peptide therapy
- GLP-1 receptor agonists
- growth-hormone secretagogues
- compounded pharmacy regulation
- telehealth pricing transparency
Articles under this byline (8)
- Does Insurance Cover GLP-1s? What Actually Gets Reimbursed, and What Doesn't
- How Much Do Peptides Cost? 2026 Monthly Prices for Sermorelin, NAD+, GHK-Cu, PT-141 and GLP-1s
- Units vs. Milligrams on a GLP-1 Syringe: Why "40 Units" Is Not a Dose
- How Long Tirzepatide Takes to Work: What the Trials Actually Measured
- Is Zepbound the Same as Tirzepatide? Brand, Molecule, and What Actually Differs
- Oral Tirzepatide: Does It Exist, and Does It Work?
Provider reviews
The 240 provider reviews on PeptideRank are published under this byline.
PeptideRank coverage of women's health research, including menstrual cycles, PCOS, pregnancy and breastfeeding precautions, and reported tissue changes.
- GLP-1 receptor agonists in women
- PCOS and metabolic therapy
- menstrual cycle effects of rapid weight loss
- pregnancy and lactation contraindications
- peptide therapy safety data
Articles under this byline (14)
- Tirzepatide, Birth Control, and PCOS Fertility: What the Evidence Actually Shows
- PT-141 (Bremelanotide): What the Evidence Actually Shows
- Vyleesi (PT-141) for Women's Libido and HSDD: What the Label and Trials Actually Show
- GLP-1 Weight Loss, Loose Skin, and Body Changes: What the Evidence Actually Shows
- Does GLP-1 Therapy Affect Your Period? What the Evidence Actually Shows
- Ozempic Face: What Is Actually Happening, and What the Evidence Shows
+8 more
- Ozempic Hands: What Is Actually Happening, and What the Evidence Shows
- Ozempic Breasts: What Is Actually Happening, and What the Evidence Shows
- Does Ozempic Cause Hair Loss? What the Research Actually Shows
- Ozempic Butt: What Is Actually Happening, and What the Evidence Shows
- PT-141 Dosage and Side Effects: What the Vyleesi Label Actually Says
- Where to Inject Tirzepatide and Semaglutide: What the Labels Actually Say
- Does Tirzepatide Cause Hair Loss? What the 2026 Evidence Actually Shows
- Is NAD+ a Peptide? What It Actually Is, and Why the Label Matters
PeptideRank coverage of published clinical evidence, drug mechanisms, FDA approval status and compounding rules.
- FDA compounding regulation (503A/503B)
- GLP-1 and growth-hormone secretagogue clinical trials
- drug shortage and approval status tracking
- peptide pharmacology
Articles under this byline (112)
- Is Compounded Tirzepatide Still Legal? What the FDA Actually Says
- Is Compounded Semaglutide Still Legal? What the FDA Actually Says
- Sermorelin vs. Ipamorelin vs. CJC-1295: What the Evidence on Growth-Hormone Secretagogues Actually Shows
- Retatrutide: What's Actually Approved, What's Actually Known, and What It Actually Costs Right Now
- Sermorelin Before and After: What the Evidence Actually Shows You Can Expect
- Tirzepatide vs. Semaglutide: What the Head-to-Head Trials Actually Show
+106 more
- Retatrutide Dosing: The Doses and Titration Schedules Actually Tested in Its Clinical Trials
- Retatrutide Side Effects: What Its Clinical Trials Have Actually Reported
- Tirzepatide Side Effects: What Its FDA Label and Pivotal Trials Actually Report
- Sermorelin vs. Tesamorelin: What the Evidence and FDA Approval Actually Show
- BPC-157: What the Evidence Actually Shows
- TB-500: What the Evidence Actually Shows
- GHK-Cu: What the Evidence Actually Shows
- KPV: What the Evidence Actually Shows
- Cagrilintide: What the Evidence Actually Shows
- Epitalon: What the Evidence Actually Shows
- DSIP: What the Evidence Actually Shows
- Melanotan II: What the Evidence Actually Shows
- MOTS-c: What the Evidence Actually Shows
- Sermorelin Side Effects: What the Trials, the Class Label, and the Cancer Data Actually Report
- What Is Compounded Tirzepatide? What Compounding Means, How It Differs From Zepbound, and What to Check
- What Is Compounded Semaglutide? How It Differs From Wegovy and Ozempic, and the One Problem That Is Unique to It
- Tirzepatide Dosage Chart: The Titration Ladder the FDA Label Actually Specifies
- Semaglutide Dosage Chart: What the Wegovy and Ozempic Labels Actually Specify
- Sermorelin Dosage: What the Evidence and Historical Filings Actually Show
- Is Sermorelin Safe? A Direct Verdict on What the Evidence Actually Shows
- Sermorelin Side Effects and Cancer: What the GH/IGF-1 Evidence Actually Shows
- Tesamorelin Dosing: What the Egrifta FDA Label Actually Specifies
- Tesamorelin Side Effects: What Egrifta's Own FDA Label Reports
- Ipamorelin vs. Sermorelin: What the Evidence Actually Shows
- MK-677 vs. Sermorelin: What the Evidence and Safety Data Actually Show
- BPC-157 Side Effects: What the Animal Studies, Human Pilot Data, and Regulatory Record Actually Show
- BPC-157 Dosage: What Studies Actually Used — Not a Recommendation
- BPC-157 Before and After: What Is Actually Documented vs. Anecdotal — and How Long It Takes
- GLOW Peptide Blend: What the Evidence Shows
- KLOW vs. GLOW Peptide: What Adding KPV Changes
- Wolverine Stack: What the Evidence Shows
- MOTS-c Dosage and Side Effects: What Studies Actually Used — Not a Recommendation
- TB-500 Dosage and Side Effects: What Studies Actually Used — Not a Recommendation
- KPV Dosage: What Studies Actually Used — Not a Recommendation
- GHK-Cu Side Effects: What the Topical Trials Report and What Injectable Use Is Missing
- NAD+: What the Evidence Actually Shows
- Glutathione: What the Evidence Actually Shows
- CJC-1295 and Ipamorelin: What the Evidence Actually Shows
- Oral Semaglutide (the Wegovy Pill): What the Evidence Actually Shows
- IGF-1 LR3: What the Evidence Actually Shows
- Semax: What the Evidence Actually Shows
- Kisspeptin: What the Evidence Actually Shows
- 5-Amino-1MQ: What the Evidence Actually Shows
- AOD-9604: What the Evidence Actually Shows
- Tesofensine: What the Evidence Actually Shows
- Dihexa: What the Evidence Actually Shows
- Gonadorelin: What the Evidence Actually Shows
- Survodutide: What the Evidence Actually Shows
- Mazdutide: What the Evidence Actually Shows
- Pemvidutide: What the Evidence Actually Shows
- BPC-157, TB-500 and KPV: The FDA Compounding Decision, Explained
- Cerebrolysin: What the Evidence Actually Shows
- Noopept: What the Evidence Actually Shows
- Selank: What the Evidence Actually Shows
- VIP (Vasoactive Intestinal Peptide): What the Evidence Actually Shows
- Thymosin Alpha-1: What the Evidence Actually Shows
- GHRP-2: What the Evidence Actually Shows
- GHRP-6: What the Evidence Actually Shows
- Hexarelin: What the Evidence Actually Shows
- Thymosin Beta-4: What the Evidence Actually Shows
- Follistatin-344: What the Evidence Actually Shows
- Liraglutide: What the Evidence Actually Shows
- NMN: What the Evidence Actually Shows
- NMN vs NAD+: What the Evidence Actually Shows
- NAD+ Nasal Spray: What the Evidence Actually Shows
- SS-31 (Elamipretide): What the Evidence Actually Shows
- Pinealon: What the Evidence Actually Shows
- Thymalin: What the Evidence Actually Shows
- Dulaglutide: What the Evidence Actually Shows
- Orforglipron: What the Evidence Actually Shows
- Exenatide: What the Evidence Actually Shows
- Pramlintide: What the Evidence Actually Shows
- Setmelanotide: What the Evidence Actually Shows
- Octreotide: What the Evidence Actually Shows
- Lanreotide: What the Evidence Actually Shows
- Bimagrumab: What the Evidence Actually Shows
- Amycretin: What the Evidence Actually Shows
- VK2735: What the Evidence Actually Shows
- Tesamorelin: What the Evidence Actually Shows
- Ipamorelin: What the Evidence Actually Shows
- CJC-1295: What the Evidence Actually Shows
- MK-677 (Ibutamoren): What the Evidence Actually Shows
- SLU-PP-332: What the Evidence Actually Shows
- Semaglutide Side Effects: What Wegovy and Ozempic Report
- GLP-1 Drugs and Muscle Loss: What the DXA Data Show
- GLP-1 Drugs and Alcohol: What the Trials Actually Show
- Ipamorelin Dosage: What the Studies Actually Administered
- CJC-1295 Dosage: What the Only Human Trial Used
- Sermorelin vs. HGH: What the Evidence Actually Shows
- Semaglutide Microdosing: What the Evidence Actually Shows
- GLP-1 and Thyroid Cancer Risk: The Warning and the Human Data
- Peptide Reconstitution and Storage: What FDA Labels Say
- NAD+ Dosage and Side Effects: What Studies Actually Used
- Glutathione Dosage and Side Effects: What Trials Used
- GHK-Cu Dosage: What the Studies Actually Administered
- BPC-157 Oral vs. Injection: Can a Capsule Do What a Shot Does?
- TB-500 vs. BPC-157: What the Evidence Actually Shows
- Retatrutide vs. Tirzepatide: What the Trials Actually Show
- 503A vs. 503B Pharmacy: What It Means for Your Compounded GLP-1 or Peptide
- How Long Does Compounded Tirzepatide or Semaglutide Last in the Fridge? (And Does It Expire?)
- Tesamorelin Before and After: What the Trials Measured (Belly Fat, Not Muscle)
- Do Peptides Show Up on a Drug Test? Employment Panels, WADA and Military Rules
- Compounded Tirzepatide or Semaglutide "With B12" (or B6): What the Additive Does and Doesn't Do
- Sermorelin Tablets vs. Injections vs. Nasal Spray: Does Oral Sermorelin Work?
- NAD+ Injections Before and After: Energy, Sleep, Skin — What the Studies Show
- GHK-Cu Before and After: What Injections and Creams Can (and Can't) Change